Compare AstraZeneca plc (AZN) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Warner Music Group Corp — how do they compare? AstraZeneca plc trades at $158.33 (market cap $248.14B), while Warner Music Group Corp trades at $24.63 (market cap $13.12B). The key difference: AstraZeneca plc is far larger — about 18.9× Warner Music Group Corp's market cap, and Warner Music Group Corp pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| AZN | WMG | |
|---|---|---|
Market Cap | $248.14B | $13.12B |
Sector | Health | Media |
52-Week High | $209.48 | $34.72 |
52-Week Low | $147.06 | $23.65 |
Enterprise Value | $275.41B | $17.42B |
Dividend Yield | 2.01% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Warner Music Group (WMG) trades at $24.62, down 6.78% in the past 24 hours, reflecting bearish technical momentum. The stock shows mixed fundamentals with recent earnings beats in Q1 and Q2 2026 but declining net income margins from 9.3% in 2022 to 5.44% in 2025. Strong institutional buying interest and a 66.66% analyst buy rating provide support despite near-term weakness.
WMG presents a compelling value opportunity with reasonable valuation multiples (P/E 20.06, P/S 1.8) and robust 9.2% projected 2026 net margin. Key risks include leadership transitions following the CFO's departure and streaming market competition, but strategic partnerships and price increases support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
